Rheumatoid Arthritis Clinical Trial
Official title:
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination With Methotrexate, Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Part A: 30 patients suffering from active rheumatoid arthritis despite continued treatment
with methotrexate will receive once daily two capsules containing either GLPG0259 (25
mg/capsule) or matching placebo, for 12 weeks. In the course of the study the patients will
be examined for severity of disease, as well as for any adverse effects that may occur. If
needed, dosing may be split to one capsule twice daily, or reduced to one capsule of 25 mg.
Part B: If results of Part A suggest test medication to have a therapeutic advantage over
placebo and to be well-tolerated, more patients will be recruited for Part B, where various
dosages will be assessed. These dosages will be established based on results from Part A.
Status | Completed |
Enrollment | 30 |
Est. completion date | April 2011 |
Est. primary completion date | April 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Must have active RA (=5 tender or painful joints on motion and =5 joints swollen AND a C-reactive protein (CRP) concentration =1.5 mg/dL). - Must have been on methotrexate for =6 months at a stable dose of 7.5-25 mg/week for =12 weeks, to be continued throughout study; - If on oral steroids, these should be at a dose =10 mg/day of prednisone eq and stable for =4 weeks prior to screening; - If on NSAIDs, these must be at a stable dose for =2 weeks prior to screening; - Women must have negative pregnancy test unless surgically sterile or post-menopausal for =1 year; - Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for =12 weeks after the last dose of study drug. - Informed consent Exclusion Criteria: - Must not have received treatment with DMARDs, other than background methotrexate; - Must not be receiving or have received RA treatment with a biological agent, except if administered in a clinical study =six months prior to screening (12 months for rituximab or other B cell depleting agents); - Must not have received any treatment with a cytotoxic agent, other than methotrexate, before screening (e.g. chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents); - Must not have received intra-articular or parenteral corticosteroid injection within four weeks prior to screening; - Must not regularly be using aspirin or any other anti-coagulant medication; - Must not have a known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator, such as anaphylaxis, requiring hospitalization; - Must not have positive serology for human immunodeficiency virus (HIV)1 or 2 or hepatitis B or C, or any history of HIV or hepatitis from any cause with the exception of hepatitis A; - Must not have a history of any inflammatory rheumatological disorders other than RA; - Must not have undergone (or planned) surgical treatments for RA; - Must not have symptoms of clinically significant illness other than RA (including but not limited to cardiopulmonary, renal, metabolic, hematologic, or psychiatric disorders) within three months prior to screening; - Must not have a history of active infections requiring intravenous antibiotics within the past four weeks; - Must not have a history of malignancy within the past five years (except for basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been treated with no evidence of recurrence); - Must not have a history of tuberculosis (TB) infection as determined by a positive diagnostic TB test result (defined as a positive QuantiFERON TB Gold test), AND a recent chest radiograph (both posterior-anterior and lateral views), read by a qualified radiologist, with evidence of current active TB or old inactive TB. - Must not have been administered a live vaccine within four weeks prior to screening; - Must not have participated in any investigational drug/device clinical study within four weeks prior to screening, in biological agents clinical studies within six months prior to screening, and B cell-depleting agent clinical studies within 12 months prior to screening; - Must not have a history within the previous two years or current evidence of drug or alcohol abuse; - Must not have any condition or circumstances which in the opinion of the Investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements, or may pose a risk to the patient's safety. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques Universitaires Saint-Luc | Brussels | |
Belgium | KU Leuven | Leuven | |
Belgium | AZ Alma | Sijsele-Damme | |
Netherlands | UMC Leiden | Leiden | |
Poland | Specjalistyczne Centrum Medyczne NZOZ NOWOMED | Kraków | |
Poland | "Linea Corporis" - Chirurgia Plastyczna Sp. z o.o. | Warszawa | |
Poland | Mokotowskie Centrum Osteoporozy S.C. | Warszawa | |
Poland | Akademia Medyczna im. Piastów Slaskich we Wroclawiu Katedra i Klinika Reumatologii i Chorób Wewnetrznych UM we Wroclawiu | Wroclaw | |
Poland | Synexus SCM Sp. z o.o. | Wroclaw | |
Russian Federation | Institution Russian Academy of Medical Sciences Scientific Research Institution of Rheumatology RAMN | Moscow | |
Russian Federation | Saint-Petersburg State Healthcare Institution "City Hospital #26" | Moscow | |
Russian Federation | State Educational Institution of Higher Professional Education "Moscow State Medico-Stomatological University of Roszdrav" at the State Healthcare Institution of city Moscow "City Clinical Ordena Trudovogo Krasnogo Znameny hospital #23 n.a. "M | Moscow | |
Russian Federation | State Educational Institution of Higher Professional Education "Moscow State Medico-Stomatological University of Roszdrav" State Healthcare Institution of City Moscow "City Clinical Ordena Trudovogo Krasnogo Znameny Hospital #23 n.a. "Medsantrud" | Moscow | |
Russian Federation | State Educational Institution of Higher Professional Education "Russian State Medical University of Roszdrav" State Healthcare Institution of City Moscow "City Clinical Hospital #15 n.a. O.M. Filatov" | Moscow | |
Russian Federation | State Healthcare Institution of City Moscow "City Clinical Hospital #1 n.a. Pirogov" | Moscow | |
Russian Federation | State Healthcare Institution of City Moscow "City Clinical Hospital #4" | Moscow | |
Russian Federation | State Healthcare Institution of City Moscow "City Clinical Hospital #7" | Moscow | |
Russian Federation | State Healthcare Institution of city Moscow "City Clinical Ordena Trudovogo Krasnogo Znameny Hospital #23 n.a. "Medsantrud" | Moscow | |
Russian Federation | Institution of Russian Academy of Sciences Saint-Petersburg Clinical Hospital RAN | St Petersburg | |
Russian Federation | Saint-Petersburg State Healthcare Institution "City Pokrovskaya Hospital" | St Petersburg | |
Russian Federation | Saint-Petersburg State Healthcare Institution "City Mariinskiy Hospital" | St-Petersburg | |
Russian Federation | State Educational Institution of Higher Professional Education "Saint-Petersburg State Pediatric Medical Academy of Roszdrav" | St. Petersburg | |
Ukraine | Chernivtsi Regional Clinical Hospital | Chernivtsi | |
Ukraine | Donetsk City Hospital No5 | Donetsk | |
Ukraine | Kharkiv City Clinical Hospital No.27 | Kharkiv | |
Ukraine | Kharkiv City Clinical Hospital No.8 | Kharkiv | |
Ukraine | Central Pool-type Clinical Hospital MoH of Ukraine | Kyiv | |
Ukraine | Institute of Gerontology AMS of Ukraine | Kyiv | |
Ukraine | Kyiv City Clinical Hospital No.3 | Kyiv | |
Ukraine | University Clinic, Crimean Medical University | Simferopol | |
Ukraine | Vinnytsia Regional Hospital | Vinnytsia | |
Ukraine | Zaporizhzhia Regional Hospital | Zaporizhzhya |
Lead Sponsor | Collaborator |
---|---|
Galapagos NV |
Belgium, Netherlands, Poland, Russian Federation, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy | The primary efficacy endpoint will be the number and percentage of subjects in each GLPG0259 dose group and placebo group achieving an American College of Rheumatology (ACR)20 (ACR20 response rate) at Week 12. | 12 weeks | No |
Secondary | Efficacy | ACR20, ACR50, ACR75 and DAS28 (and components) at weeks 1, 2, 4, 8 and 12; | intermediate timepoints for 12 weeks | No |
Secondary | Safety | At each return visit, patients will be asked about adverse events, and undergo examination of heart (ECG) and bloodpressure; blood- and urine-samples will be collected to monitor organ functions. | 12 weeks | No |
Secondary | Pharmacokinetics | On several timepoints throughout the study bloodsamples will be taken from the patient to establish the amount of the study medication in the blood, and to determine how long it stays in the blood. | 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |